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Toxoplasma gondii is an important food- and waterborne opportunistic pathogen that causes severe disease
in immunocompromised patients. T. gondii has an unusual clonal population structure consisting of three
widespread lineages known as I, II, and III. To establish the genotypes of strains of T. gondii associated with
human toxoplasmosis, we have developed a set of four highly sensitive and polymorphic nested PCR markers.
Multiplex nested PCR analysis was used to genotype parasites in cerebral spinal fluid samples from 8 of 10
human immunodeficiency virus-positive patients. Remarkably, a majority of these patients had infections with
type I strains or strains containing type I alleles, despite the fact that this lineage is normally uncommon in
humans and animals. Multiplex analysis of these four unlinked makers was able to distinguish all three
common genotypes and also detected two strains with mixed genotypes. Further analysis based on sequencing
of a polymorphic intron revealed that one of these recombinant strains was an exotic lineage distinct from the
archetypal clonal lineages. The multiplex nested PCR analysis described here will be useful for analyzing the
contribution of parasite genotype to toxoplasmosis.
Toxoplasma gondii is a common cause of infection in many
warm-blooded animals, including humans (6). Infection in hu-
mans generally occurs either by consuming tissue cysts in raw
or undercooked meat or by accidental ingestion of oocysts shed
in the feces of infected cats (20). Following acute infection,
T. gondii differentiates into tissue cysts that reside in the mus-
cles and brain. Most cases of human infection are mild, but
devastating disease can occur in congenitally infected children
(33) and in immunocompromised individuals, including pa-
tients with AIDS (15, 19). Toxoplasmic encephalitis (TE) is a
serious clinical complication in immunocompromised patients,
especially in patients with AIDS. The majority of these cases
are thought to result from recurrence of chronic infections
following declining cellular immunity (18). Prophylactic anti-
biotics that were adopted to prevent Pneumocystis pneumonia
also resulted in decreased incidence of TE. Additionally, the
introduction of advanced highly active antiretroviral therapy
(HAART) further resulted in dramatically reduced incidence
compared to pre-HAART therapy (25, 26). However, in many
geographic regions of the world, antibiotic or HAART thera-
pies are not widely available, and hence, toxoplasmosis contin-
ues to be a significant problem in human immunodeficiency
virus (HIV) patients, as cited, for example, in recent studies
from Italy (3), Brazil (32), Malaysia (24), and Ethiopia (4).
T. gondii has a highly unusual population structure consist-
ing of three clonal lineages known as types I, II, and III, which
are widespread in North America and Europe (5, 14). Studies
of genetic polymorphism reveal that at each locus there exist
only two alleles, indicating that these three lineages arose from
a common source and that they have since undergone limited
genetic exchange (9, 30). A small number (less than 5%) of
isolates have mixtures of the two-allele patterns seen in the type
strains, indicating that they are natural recombinants. Even less
common are exotic strains, which have many unique polymor-
phisms, indicating they have a more ancient origin. The clonal
lineages share the trait of direct oral infectivity to intermediate
hosts, thus bypassing the need for sexual recombination (28, 30).
Direct oral transmission presumably led to the recent emergence
and widespread success of the clonal lineages. It has recently been
suggested that a wider range of genotypes might be found in
geographically remote areas where transmission may rely more
often on the sexual phase, which only occurs in cats (1).
Studies with mice have shown that infections with the dif-
ferent clonal lineages of T. gondii result in very different out-
comes. Type I strains are highly virulent, whereas type II and
type III are relatively nonvirulent (29). The enhanced virulence
of type I strains is in part due to overstimulation of a Th1
immune response that leads to pathology (23). However, it
remains uncertain to what extent the genotype of the parasite
directly contributes to the clinical severity of human toxoplas-
mosis. Comparison of the genotypes of T. gondii strains asso-
ciated with animal versus human infections showed an in-
creased frequency of type I strains in AIDS patients, although
a majority of infections were caused by type II strains (14).
Type I strains were also frequently associated with recurrent
ocular toxoplasmosis observed in patients that were immuno-
compromised (10). These studies suggest that type I strains are
more pathogenic or more likely to cause infection in immuno-
compromised patients. However, in most studies centered in
North America and Europe, type II strains are the most prev-
alent cause of human toxoplasmosis both in congenital infec-
tion (2, 5, 14) and in AIDS patients (13, 14).
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The continued expansion of HIV on a global level has in-
creased the need for more sensitive and efficient diagnostic tests
for opportunistic infections. Nested PCR (nPCR) has been used
widely in different studies for sensitive diagnosis of toxoplasmosis
(22, 27). In most cases, the sensitivity of specific detection of the
assay is of primary concern. However, most of the highly repeti-
tive markers that provide sensitive detection (i.e., B1, rRNA
genes) are not useful for genotyping the parasite due to a relative
absence of polymorphisms. We have previously described an
nPCR assay for the SAG2 locus that allows sensitive typing of all
three lineages, and this has now been widely adopted by other
groups (13). However, the limitation of using a single locus for
typing is that mixed strains or exotic genotypes will be misclassi-
fied as having a simple genotype. Mixed genotypes may be more
common in some regions, and such strains may present different
clinical complications following infection in humans. Conse-
quently, in the present study, we developed four independent
nPCR markers to provide rapid and specific diagnosis of toxo-
plasmosis in clinical samples.
MATERIALS AND METHODS
Clinical isolates. We analyzed 11 clinical samples (designated WU01 through
WU11) collected during the period of 1990 to 1996. Analysis was performed
retrospectively on cerebral spinal fluid (CSF) samples that had been collected for
other routine diagnostic tests. All of the patients were HIV-positive immuno-
compromised patients. Several of these had presumptive TE based on the pres-
ence of single or multiple lesions observed on computed tomography or magnetic
resonance scans of the central nervous system. WU02 was from an HIV-positive
patient who was diagnosed with central nervous system lymphoma but was
negative for Toxoplasma serology and B1 PCR (data not shown). We were
unable to obtain additional clinical data on the remaining samples, in part due to
patient confidentiality issues. CSF samples were processed using a DNeasy tissue
kit (QIAGEN, Inc., Valencia, CA) to extract DNA for PCR assays. Studies were
conducted with approval from the Human Studies Committee at Washington
University School of Medicine.
Type strains. Reference strains for each of the clonal lineages consisted of type
I RH-88 (ATCC 50838), type II Me49 (ATCC 50840), and type III CTG (ATCC
50842). T. gondii cell lysates from the clonal type strains were used directly as
DNA templates for the PCR assays. Parasite strains were grown in human
fibroblast cells and harvested after host cell lysis. Samples were resuspended in
phosphate-buffered saline at a concentration of approximately 106 cells/ml and
digested with 10 g/ml proteinase K at 55°C for 2 h. Lysates were then heat
inactivated at 95°C for 15 min and stored frozen at 20°C until use.
Sensitivity controls. Reference T. gondii strain RH was grown in human
fibroblast cells, and parasites were harvested after host cell lysis. Parasite cells
were resuspended in phosphate-buffered saline, counted using a hemocytometer,
and diluted into aliquots containing 1, 2.5, 5, or 10 parasites. Defined numbers of
parasites were added to 100 l of normal human human CSF from Toxoplasma-
negative donors and processed using the DNeasy tissue kit (QIAGEN, Inc.,
Valencia, CA) to extract DNA. Extracted DNA samples (10 l) were used
directly for multiplex PCR in a final volume of 50 l. In the second round of
amplification, 5 l of product from the multiplex reaction was used for gene-
specific PCR amplifications as described below. Final products were resolved in
1% agarose gels stained with ethidium bromide.
Genotyping of isolates by PCR-RFLP. To determine the genotypes of T. gondii
strains in clinical samples, we developed highly sensitive nPCR markers from
four different genetic markers: 5-SAG2, 3-SAG2, BTUB, GRA6, and SAG3.
The presence of sequence polymorphism within each locus results in distinctive
restriction fragment length polymorphism (RFLP) patterns that were used to
assign alleles for each type strain. Multiplex PCR using external primers for four
different markers was used for the initial round of amplification. PCR was carried
out in a 50-l reaction mixture consisting of 5 l of 10 PCR buffer without
MgCl2 (Sigma, St. Louis, MO), 4 l deoxynucleoside triphosphates (2.5 M
each), 3 l of 25 mM MgCl2, 1.5 l each primer (50 M), and 0.5 l AmpliTaq
(5 U/l) (Sigma). Amplification was conducted for 40 cycles at an annealing
temperature of 55°C. PCR-amplified products (5 l) were then used for second-
round amplification of each marker separately in a 25-l-volume reaction mix-
ture (all components were at the same concentrations as given above) using
primers given in Table 1. Positive controls consisted of cell lysate from T. gondii
type I (RH), type II (Me49), or type III (CTG) strains. Negative controls
consisted of DNA-free water and proteinase K-treated cell lysate of noninfected
HFF cells. The amplified fragments were digested with appropriate restriction
enzymes for different markers, and the fragments were analyzed by 3% agarose
gel electrophoresis, stained with ethidium bromide, and imaged by Alpha Im-
ager, version 5.5 (Alpha Innotech Corp., San Leandro, CA). Estimates of the
sizes of fragments were based on comparison to X 174 DNA digested with
HaeIII (New England Biolabs, Beverley, MA).
Intron sequencing. To determine the relative divergence between T. gondii
strains, the frequency of single-nucleotide polymorphisms (SNPs) present in the
UPRT-1 intron sequence (GenBank accession no. AY143142) was analyzed (30).
Nested primers were used to amplify the genomic region flanking this intron: exter-
nal primers, UPRT1 (EXT) F (5-TCCACAGGGCTTCTAAAAT-3) and UPRT1
(EXT) R (5-GAGTTGAGAACAGGCTTCAG-3); internal primers, UPRT-F1
(5-CCCGATATTCGACAAACGAC-3) and UPRT-R1 (5-GAGCCGTCTGCT
TCATGAGC-3). PCR products were purified using QIAquick PCR purification kit
(QIAGEN) according to the manufacturer’s instructions. Sequencing was done from
three independent templates using BigDye cycle sequencing (Applied Biosystems,
Foster City, CA) (conducted by SeqWright DNA Technology Services, Houston,
TX). Nucleotide sequences were analyzed using Vector NTI, version 9 (InforMax;
Invitrogen Life Sciences, Carlsbad, CA). CLUSTALX (12) was used to align the
sequences for comparison.
RESULTS
To provide for highly sensitive genotyping of T. gondii, we
developed four independent nPCR markers, SAG2, BTUB,
TABLE 1. Primers used for nested PCR amplification of T. gondii
Locus
(chromosome location) External primer (sequence [5–3]) Internal primer (sequence [5–3])
Source and/or
reference
5-SAG2 (VIII) SAG2.F4 (GCTACCTCGAACAGGAACAC) SAG2.F (GAAATGTTTCAGGTTGCTGC) 13
SAG2.R4 (GCATCAACAGTCTTCGTTGC) SAG2.R2 (GCAAGAGCGAACTTGAACAC) 13
3-SAG2 (VIII) SAG2.F3 (TCTGTTCTCCGAAGTGACTCC) SAG2.F2 (ATTCTCATGCCTCCGCTTC) 13
SAG2.R3 (TCAAAGCGTGCATTATCGC) SAG2.R (AACGTTTCACGAAGGCACAC) 13
BTUB (IX) Btb (ext)F (TCCAAAATGAGAGAAATCGT) Btb-F (GAGGTCATCTCGGACGAACA) This study
Btb (ext)R (AAATTGAAATGACGGAAGAA) Btb-R (TTGTAGGAACACCCGGACGC) This study
GRA6 (XI) GRA6-F1x (ATTTGTGTTTCCGAGCAGGT) GRA6-F1 (TTTCCGAGCAGGTGACCT) This study; 8
GRA6-R1 (GCACCTTCGCTTGTGGTT) GRA6-R1x (TCGCCGAAGAGTTGACATAG) This study; 8
SAG3 (XII) P43S1 (CAACTCTCACCATTCCACCC) P43AS2 (CACAAGGAGACCGAGAAGGA) 11
P43AS1 (GCGCGTTGTTAGACAAGACA) P43S2 (TCTTGTCGGGTGTTCACTCA) 11
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GRA6, and SAG3, which are located on chromosomes VIII,
IX, X, and XII, respectively (Table 1) (16). Because clinical
samples are often available in limited quantity, a multiplex
nPCR was employed using external primers for all four loci in
the initial round of amplification. Internal primers were then
selected to separately amplify the four loci. To test the sensi-
tivity of the nested PCR assay, normal human CSF was spiked
with freshly isolated parasites (1, 2.5, 5, and 10 parasites) and
used for multiplex PCR amplification, followed by nested PCR
amplifications for gene-specific markers. All of the nested PCR
markers shown in Fig. 1 were readily amplified from CSF
samples spiked with 10 parasites (Fig. 1). SAG3 was also de-
tected when as few as five parasites were spiked in human CSF
(Fig. 1). Negative controls remained free of amplified products
(Fig. 1).
The nested PCR assay for the SAG2 locus (13) and SAG3
locus (11) have been described previously. The combination of
polymorphisms in the 5 and 3 ends of the SAG2 gene allow
typing of all three lineages based on a unique combination of
alleles. The design of nPCR markers for GRA6 (8) was modified
from a previous study that defined polymorphism in this gene.
Each of these markers contains several closely spaced polymor-
phisms that result in three-way typing with a single restriction
enzyme (Fig. 2). Digestion of the amplified product of BTUB
with BsiEI distinguished genotype I (allele 1) from genotypes II
and III (allele 2) and with TaqI distinguished genotype II (allele
2) from genotypes I and III (allele 1) (Fig. 2). Consequently, each
of the four markers can unambiguously detect all three genotypes
based on distinct RFLP patterns.
We examined 11 CSF samples collected during the period of
1990 to 1996 from immunocompromised patients (HIV posi-
tive) patients. Six of these patients were clinically diagnosed as
having confirmed (WU01, WU03, and WU05) or suspected
(WU04, WU07, and WU08) TE (Table 2). Classification was
based on having two or more of the following criteria: (i)
positive serological response to T. gondii, (ii) single or multiple
contrast-enhancing lesions on computed tomography or mag-
netic resonance scan, (iii) progressive cognitive or motor im-
pairment, and (iv) response to anti-T. gondii therapy. One
HIV-positive patient with no history of toxoplasmosis (WU02)
but with lymphoma was selected as a negative control. Multi-
plex nPCR was used to detect and identify the genotypes of
T. gondii present in these clinical samples.
Following the initial multiplex PCR using external primers, no
amplification products were observed (data not shown), indicat-
ing that the amount of parasite DNA present in these clinical
samples was likely very low. In the second round of amplification,
8 of 11 samples gave positive amplicons for one or more of the
markers (data not shown) using separate sets of internal primers
for the four nPCR markers. All of the confirmed and suspected
cases of TE were positive for at least one marker. WU02, which
was a negative control, was consistently negative for all markers.
Two of the patients for whom TE was not a suspected diagnosis
(WU10 and WU11) also remained negative in all analyses. No
products were detected from negative controls (water and pro-
teinase K-treated cell lysate of noninfected fibroblast cultures)
used to check for contamination.
Following restriction digestion and gel electrophoresis of the
products, the strains were classified based on the alleles shown
in Fig. 2. Six (WU01, WU03, WU04, WU07, WU08, and
WU09) of 8 positive clinical samples possessed type I alleles at
some or all of the markers (Table 2). Four of these samples
were supported by two or more independent markers, whereas
the remaining 2 samples were only supported by the marker
SAG3. SAG3 is the most sensitive marker within this set
(Fig. 1), thus it is typically the easiest to detect when parasite
DNA is limiting. Due to limited sample amounts, we were not
able to successfully amplify and type the remaining loci for
these samples. WU06 showed a type III genotype in all four
nPCR markers. Interestingly, sample WU05 showed an un-
usual genotype and possessed type I (at SAG2 and BTUB
loci), type II (at the GRA6 locus), and type III (at the SAG3
locus) alleles at different loci (Fig. 2; Table 2). These results
gave the first indication that the T. gondii strain present in
WU05 carried a novel nonarchetypal genotype.
The true extent of polymorphism between alleles cannot be
fully assessed by RFLP analysis, thus we determined the se-
quence of a polymorphic intron in the UPRT gene as described
previously (30). The frequency of SNPs present in the UPRT-1
sequence of WU05 was compared to the archetypal clonal
genotypes, and it was found to contain the normal biallelic
pattern and to have four novel SNPs (Table 3). This finding
FIG. 1. Nested PCR amplification of markers (5-SAG2, 3-SAG2, SAG3, BTUB, and GRA6) from control CSF spiked with parasites. The
center four lanes of each group represent the samples spiked with 1, 2.5, 5, and 10 freshly isolated parasites added to negative CSF, respectively.
The negative controls () correspond to water blanks (first and last lane of each group). Products were resolved on a 1% agarose gel stained with
ethidium bromide. Lanes M, molecular mass markers from X174 digested with HaeIII.
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indicates that WU05 contains sufficient novel SNPs in its ge-
nome to classify this strain as exotic. By comparison, intron
analysis of WU08 revealed a type III sequence without evi-
dence of any additional mutations (Table 3).
DISCUSSION
We have developed a sensitive nPCR assay for multiplex
analysis of the genotypes of T. gondii in clinical samples. Ap-
plication of this method to CSF samples from patients with
confirmed or presumptive TE revealed a striking percentage of
strains with a type I genotype. In addition, the combination of
4 independent markers was useful for identifying a mixed
strain, which upon further analysis turned out to have an exotic
genotype. The multiplex nPCR method is highly sensitive and
specific and provides comprehensive genotyping from small
amounts of clinical material. Application of this methodology
to a broader set of samples should be useful in classifying
strains of T. gondii that cause toxoplasmosis.
Genotyping of T. gondii samples from clinical infections is
complicated by the chronic nature of the infection, which is
characterized by semidormant tissue cysts and an absence of
circulating parasites. For these reasons, we lack good baseline
data on the strains of parasite that cause clinically unapparent
infections in humans (the majority of cases). While recent
attempts to develop serological tests for genotyping infections
show promise (17), they lack the ability to unambiguously
identify all three lineages and they have not yet been widely
applied. Furthermore, the kinetics of parasite dissemination dur-
ing infection is poorly understood, and there are no systematic
protocols for reliably detecting parasites in patients with toxoplas-
mosis. One of the advantages of the method described here is that
it can be conducted on small samples of CSF, amniotic fluid, or
buffy coats, typically using materials that are collected in the
course of performing other clinical tests. The sensitivity of the
multiplex nPCR method described here is estimated to be be-
tween 5 to 10 parasites, which makes it well suited to clinical
FIG. 2. RFLP analysis of type strains and a mixed clinical isolate of T. gondii using 4 nested PCR markers. Agarose gel electrophoresis
of undigested and restriction-digested products for type strains (type I RH, type II Me49, and type III CTG; lanes I, II, and III, respectively)
and a mixed-genotype isolate (lanes WU05) is shown. Products were resolved on 3% agarose gels stained with ethidium bromide. Lanes: Neg,
negative PCR control; M, molecular mass markers corresponding to X 174 digested with HaeIII. SAG2 typing was based on a previously
reported method (13). GRA6 typing was adapted from a previously reported method (8). SAG3 typing was adapted from a previously reported
method (11).
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samples containing small numbers of organisms. Thus, wider ap-
plication of this methodology may yield a broader data set for
drawing conclusions about the occurrence of toxoplasmosis asso-
ciated with particular genotypes of the parasite.
Previous studies have shown that the type II lineage is the
most prevalent in animals and humans (5, 13, 14). Since toxo-
plasmosis is acquired as a food-borne or waterborne pathogen
(20), infections in agricultural animals and cats provide the
reservoir for human infection. Type II strains are the most
abundant, while type I strains are relatively rare in agricultural
and wild animals from North America (7, 14, 21). However, an
elevated frequency of type I strains is observed in some studies
of immunocompromised patients. For example, Howe and
Sibley reported a slight increase in the frequency of type I
strains in HIV patients with advanced TE (14). A study of
recurrent retinal toxoplasmosis in immunocompromised pa-
tients also reported an elevated frequency of type I strains or
strains bearing type I alleles (11). A larger study of immuno-
compromised patients may reveal if this pattern is really due to
increased pathogenicity of type I strains or simply due to small
sample sizes. Type I strains are capable of causing lethal in-
fection in mice (23, 29), and this trait has been linked to a
parasite gene on chromosome VIIa that is conserved among all
type I strains examined (31).
The majority of samples examined in the present study were of
the type I genotype or at least contained the type I alleles. Six of
8 positive samples contained type I alleles (75%), while the fre-
quency of type I strains in animals is in the range of 5 to 10% (13,
21). For several of the samples, only a single marker (SAG3) was
positive in the PCR analysis; consequently, it is possible that these
strains have a mixed genotype consisting of some type I alleles.
While we cannot be sure of the reason for the high frequency of
type I alleles and strains, it is quite likely that the samples studied
here contain a selection bias, since the samples were obtained due
to progressive neurological deterioration.
All of the patients in the present study were receiving anti-
viral therapy, although many of the patients had advanced
AIDS and likely concomitant reduced immune function. Due
to the retrospective nature of the study, it was not possible to
access patient records for all of the samples. However, from
the available data, the range of clinical severity of the patients
was substantial, as some patients had severe TE characterized
by multifocal lesions (WU01, WU03, and WU05). Others had
a single lesion (WU04 and WU08) and, in some cases, were not
suspected of having TE initially (patient WU08, for example,
had a negative Toxoplasma serology). It is unlikely that the
positive result obtained here by PCR is due to a false positive,
as we never observed contamination in any of the control
reactions. However, sequencing the UPRT-1 intron for this
isolate revealed a type III sequence. These data are consistent
with this strain being a natural recombinant between the type
I and III lineages. Due to the sensitivity of the nPCR assay
described here, it may also provide a rapid means of establish-
ing the presence of T. gondii DNA in clinical samples.
TABLE 2. Genotypes of human toxoplasmosis samples tested by multiplex nested PCR
Sample HIVstatus Diagnosis Toxoplasma serology
Allele type at locus:
Genotype
5 SAG2a 3 SAG2b BTUB(BsiEI, TaqI) SAG3 GRA6
WU01  TE, multiple lesions IgG f positive c   1 1 I
WU03  TE, large, multiple lesions IgG positive, IgM negative 1   1  I
WU05  TE, multiple lesions, ring enhancing IgG positive 1 1 1, 1 3 2 Mixed
WU04  TE, single lesion NAe 1 1    I
WU07  Small lesions, white matter NA  1  1 1 I
WU08  Single lesion, nonenhancing Negative    1  I/IIId
WU06  NA NA 2 1 2, 1 3 3 III
WU09  NA NA    1  I
WU10  NA NA      
WU11  NA NA      
WU02  Lymphoma Negative      
a Genotypes I and II are the same.
b Genotypes I and III are the same.
c , negative amplification product.
d This strain has a recombinant genotype based on intron sequence data shown in Table 3.
e NA, data not available.
f IgG, immunoglobulin G.
TABLE 3. Summary of polymorphisms in UPRT-1 intron 1
from T. gondii strains
Allele
type Strain Source
UPRT-1 nucleotide at SNP positiona:
176 197 207 335 385 386 389 409 414 442
I RH Human A C C T C C C G G C
GT1 Goat A C C T C C C G G C
II B7 Sheep C T G C T C C T G C
DEG Human C T G C T C C T G C
III CTG Cat C T G C T C C T G C
VEG Human C T G C T C C T G C
Clinical
samples
WU08 Human C T G C T C C T G C
WU05 Human A C C C C G A G A G
a Nucleotides are shown at the numbered positions that contained one or more
SNPs. The total intron size is 443 bp, and positions not indicated were identical
for all strains. Size is based on the noncoding region including the GT/AC splice
site. Biallelic polymorphisms are found in the type strains and WU08, which has
a type III genotype. WU05 contains biallelic polymorphisms shared with the
clonal types and also contains 4 unique SNPs (bold).
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We previously described an nPCR method for genotyping
the three predominant lineages of T. gondii based on the SAG2
locus (13). While this marker provides accurate genotyping of
the majority of strains, it is not capable of detecting recombi-
nant or exotic strains. The advantage of using the combination
of 4 independent markers in the present study is that they are
much more likely to detect recombinant genotypes. Recombi-
nation between the clonal lineages occurs rarely in the wild and
is seen in 1 to 5% of strains sampled. These strains contain the
archetypal biallelic pattern, but they have been shuffled due to
genetic recombination that occurs via meiosis following coin-
fection in the cat. A second class of strains is typified by having
a significantly greater level of polymorphism, and these stains
have been classified as exotic (9, 30). Exotic strains predate the
origin of the archetypal clonal lineages, and they can readily be
distinguished at the nucleotide level by their divergence from
the clonal lineages (typically they contain 2 to 3% higher levels
of nucleotide polymorphism).
Notably, one strain analyzed here (WU05) was initially
thought to have a recombinant genotype based on the combi-
nation of alleles at 4 different makers. However, when the
intron from the UPRT-1 gene was sequenced, this strain
proved to have additional polymorphisms not seen in the ar-
chetypal clones. The patient presenting with this exotic strain
of T. gondii was originally from Africa. While we cannot be
sure where the patient acquired this infection, it may be sig-
nificant that its genotype and intron sequence matches closely
to another recently reported exotic lineage isolated in France
known as strain GPHT (1), and it is similar to other strains
isolated in Africa (M. L. Darde´, personal communication). The
nested amplification and sequencing method for the UPRT-1
intron described here will be useful for typing additional
strains that are suspected to be exotic.
While a strong pattern of clonality predominates in Europe
and North America, it has been suggested that regions that are
geographically remote may harbor strains of T. gondii that are
genetically more diverse (1). For example, strains isolated from
French Guyana have an unusual genotype that is distinct from
the archetypal lineages (1). Limited sampling has been done
from Africa, Asia, and South America, and it is possible that
alternative clonal lineages or exotic genotypes of T. gondii
predominate there rather than the clonal pattern seen in
Europe and North America. More extensive analysis of the
strains of T. gondii associated with clinical disease may be
beneficial in deciphering the genetic complexity of the parasite
and in providing diagnosis of toxoplasmosis.
ACKNOWLEDGMENTS
We thank Daniel K. Howe (Veterinary Science Department, University
of Kentucky), who performed preliminary studies; Bill Campbell and Bill
Mulford, who assisted in sample acquisition; and Julie Suetterlin, who
provided technical assistance.
This work was supported by an NIH grant (AI36629) to L.D.S. D.B.C.
was supported by NIH grants AI38858, NS32228, and NIMH-22005.
REFERENCES
1. Ajzenberg, D., A. L. Ban˜uls, C. Su, A. Dume`tre, M. Demar, B. Carme, and
M. L. Darde´. 2004. Genetic diversity, clonality and sexuality in Toxoplasma
gondii. Int. J. Parasitol. 34:1185–1196.
2. Ajzenberg, D., N. Cogne, L. Paris, M. H. Bessieres, P. Thulliez, D. Fillisetti,
H. Pelloux, P. Marty, and M. L. Darde´. 2002. Genotype of 86 Toxoplasma
gondii isolates associated with human congenital toxoplasmosis and correla-
tion with clinical findings. J. Infect. Dis. 186:684–689.
3. Antinori, A., D. Larussa, A. Cingolani, P. Lorenzini, S. Bossolasco, M. G.
Finazzi, M. Bongiovanni, G. Guaraldi, S. Grisetti, B. Vigo, B. Gigli, A.
Mariano, E. R. Dalle Nogare, M. De Marco, F. Moretti, P. Corsi, N. Abrescia, P.
Rellecati, A. Castagna, C. Mussini, A. Ammassari, P. Cinque, A. d’Arminio
Monforte, and Italian Registry Investigative NeuroAIDS. 2004. Prevalence,
associated factors, and prognostic determinants of AIDS-related toxoplas-
mic encephalitis in the era of advanced highly active antiretroviral therapy.
Clin. Infect. Dis. 39:1681–1691.
4. Bane, A., A. G. Yohannes, and D. Fekade. 2003. Morbidity and mortality of
adult patients with HIV/AIDS at Tikur Anbessa Teaching Hospital, Addis
Ababa, Ethiopia. Ethiop. Med. J. 41:131–140.
5. Darde´, M. L., B. Bouteille, and M. Pestre-Alexandre. 1992. Isoenzyme anal-
ysis of 35 Toxoplasma gondii isolates and the biological and epidemiological
implications. J. Parasitol. 78:786–794.
6. Dubey, J. P., and C. P. Beattie. 1988. Toxoplasmosis of animals and man.
CRC Press, Boca Raton, Fla.
7. Dubey, J. P., D. H. Graham, E. Dahl, C. Sreekumar, T. Lehmann, M. F.
Davis, and T. Y. Morishita. 2003. Toxoplasma gondii isolates from free-
ranging chickens from the United States. J. Parasitol. 89:1060–1062.
8. Fazaeli, A., P. E. Carter, M. L. Darde´, and T. H. Pennington. 2000. Molecular
typing of Toxoplasma gondii strains by GRA6 gene sequence analysis. Int. J.
Parasitol. 30:637–642.
9. Grigg, M. E., S. Bonnefoy, A. B. Hehl, Y. Suzuki, and J. C. Boothroyd. 2001.
Success and virulence in Toxoplasma as the result of sexual recombination
between two distinct ancestries. Science 294:161–165.
10. Grigg, M. E., and J. C. Boothroyd. 2001. Rapid identification of virulent type
I strains of the protozoan parasite Toxoplasma gondii by PCR-restriction
fragment length polymorphism analysis of the B1 gene. J. Clin. Microbiol.
39:398–400.
11. Grigg, M. E., J. Ganatra, J. C. Boothroyd, and T. P. Margolis. 2001. Unusual
abundance of atypical strains associated with human ocular toxoplasmosis.
J. Infect. Dis. 184:633–639.
12. Higgins, D. G., J. D. Thompson, and T. J. Gibson. 1996. Using CLUSTAL
for multiple sequence alignments. Methods Enzymol. 266:382–402.
13. Howe, D. K., S. Honore´, F. Derouin, and L. D. Sibley. 1997. Determination
of genotypes of Toxoplasma gondii strains isolated from patients with toxo-
plasmosis. J. Clin. Microbiol. 35:1411–1414.
14. Howe, D. K., and L. D. Sibley. 1995. Toxoplasma gondii comprises three
clonal lineages: correlation of parasite genotype with human disease. J. In-
fect. Dis. 172:1561–1566.
15. Israelski, D. M., and J. S. Remington. 1993. Toxoplasmosis in the non-AIDS
immunocompromised host. Curr. Clin. Top. Infect. Dis. 13:322–356.
16. Khan, A., S. Taylor, C. Su, A. J. Mackey, J. Boyle, R. H. Cole, D. Glover, K.
Tang, I. Paulsen, M. Berriman, J. C. Boothroyd, E. R. Pfefferkorn, J. P.
Dubey, D. S. Roos, J. W. Ajioka, J. C. Wootton, and L. D. Sibley. 2005.
Composite genome map and recombination parameters derived from three
archetypal lineages of Toxoplasma gondii. Nucleic Acids Res. 33:2980–2992.
17. Kong, J. T., M. E. Grigg, L. Uyetake, S. F. Parmley, and J. C. Boothroyd.
2003. Serotyping of Toxoplasma gondii infections in humans using synthetic
peptides. J. Infect. Dis. 187:1484–1495.
18. Luft, B. J., R. Hafner, A. H. Korzun, C. Leport, D. Antoniskis, E. M. Bosler,
D. D. Bourland, R. Uttamchandani, J. Fuhrer, J. Jacobson, P. Morlat, J.-L.
Vilde, and J. S. Remington. 1993. Toxoplasmic encephalitis in patients with
the acquired immunodeficiency syndrome. N. Engl. J. Med. 329:995–1000.
19. Luft, B. J., and J. S. Remington. 1992. Toxoplasmic encephalitis in AIDS.
Clin. Infect. Dis. 15:211–222.
20. Mead, P. S., L. Slutsker, V. Dietz, L. F. McCaig, J. S. Bresee, C. Shapiro,
P. M. Griffin, and R. V. Tauxe. 1999. Food-related illness and death in the
United States. Emerg. Infect. Dis. 5:607–625.
21. Mondragon, R., D. K. Howe, J. P. Dubey, and L. D. Sibley. 1998. Genotypic
analysis of Toxoplasma gondii isolates in pigs. J. Parasitol. 84:639–641.
22. Montoya, J. G., and O. Liesenfled. 2004. Toxoplasmosis. Lancet 363:1965–
1976.
23. Mordue, D. G., F. Monroy, M. La Regina, C. A. Dinarello, and L. D. Sibley.
2001. Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines.
J. Immunol. 167:4574–4584.
24. Nissapatorn, V., C. Lee, K. F. Quek, C. L. Leong, R. Mahmud, and K. A.
Abdullah. 2004. Toxoplasmosis in HIV/AIDS patients: a current situation.
Jpn. J. Infect. Dis. 57:160–165.
25. Palella, F. J., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A.
Satten, D. J. Aschman, S. D. Holmberg, and The HIV Outpatient Study Inves-
tigators. 1998. Declining morbidity and mortality among patients with advanced
human immunodeficiency virus infection. N. Engl. J. Med. 13:853–860.
26. Phillips, A. N., S. Grabar, J. M. Tassie, D. Costagliola, J. Lundgren, M.
Egger, EuroSIDA, French Hospital Database on HIV, and Swiss HIV Cohort
Study Group. 1999. Use of observational databases to evaluate the effec-
tiveness of antiretroviral therapy for HIV infection: comparison of cohort
studies with randomized trials. AIDS 13:2075–2082.
5886 KHAN ET AL. J. CLIN. MICROBIOL.
27. Remington, J. S., P. Thulliez, and J. G. Montoya. 2004. Recent develop-
ments for diagnosis of toxoplasmosis. J. Clin. Microbiol. 42:941–945.
28. Sibley, L. D. 2003. Recent origins among ancient parasites. Vet. Parasitol.
115:185–198.
29. Sibley, L. D., and J. C. Boothroyd. 1992. Virulent strains of Toxoplasma
gondii comprise a single clonal lineage. Nature (London) 359:82–85.
30. Su, C., D. Evans, R. H. Cole, J. C. Kissinger, J. W. Ajioka, and L. D. Sibley.
2003. Recent expansion of Toxoplasma through enhanced oral transmission.
Science 299:414–416.
31. Su, C., D. K. Howe, J. P. Dubey, J. W. Ajioka, and L. D. Sibley. 2002.
Identification of quantitative trait loci controlling acute virulence in Toxo-
plasma gondii. Proc. Natl. Acad. Sci. USA 99:10753–10758.
32. Vidal, J. E., F. A. Colombo, A. C. de Oliveira, R. Focaccia, and V. L.
Pereira-Chioccola. 2004. PCR assay using cerebrospinal fluid for diagnosis of
cerebral toxoplasmosis in Brazilian AIDS patients. J. Clin. Microbiol. 42:
4765–4768.
33. Wong, S., and J. S. Remington. 1994. Toxoplasmosis in pregnancy. Clin.
Infect. Dis. 18:853–862.
VOL. 43, 2005 GENOTYPING OF TOXOPLASMA 5887
